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The purpose of the study was to calculate population-based survival rates for osteosarcoma (OS) and Ewing’s sarcoma (ES) in Great
Britain during 1980–1994, determine proportions of patients treated at specialist centres or entered in national and international
clinical trials, and investigate effects of these factors on survival. Data on a population-based series of 1349 patients with OS and 849
with ES were compiled from regional and national cancer registries, UK Children’s Cancer Study Group, regional bone tumour
registries and clinical trials. Follow-up was through population registers. Survival was analysed by actuarial analysis with log-rank tests
and by Cox’s proportional hazards analysis. Five-year survival rates during 1980–1984, 1985–1989 and 1990–1994 were 42% (95%
CI: 37, 46), 54% (95% CI: 50, 59) and 53% (95% CI: 48, 57), respectively, for OS and 31% (95% CI: 26, 37), 46% (95% CI: 40, 51) and
51% (95% CI: 45, 57) for ES. Proportions of patients treated at a supraregional bone tumour centre or a paediatric oncology centre in
the three quinquennia were 36, 56 and 67% for OS and 41, 60 and 69% for ES. In 1983–1992, 48% of OS patients were entered in a
national trial; for ES, 27% were entered in 1980–1986 and 54% in 1987–1994. Survival was similar for trial and nontrial patients with
OS. For ES, trial patients had consistently higher 5-year survival than nontrial patients: 1980–1986, 42 vs 30%; 1987–1992, 59 vs 42%;
1993–1994, 54 vs 43%. During 1985–1994, patients with OS or ES whose main treatment centre was a nonteaching hospital had
lower survival rates. In multivariate analyses of patients diagnosed during 1985–1994 that also included age, sex, primary site, surgical
treatment centre, the results relating to main treatment centre for both OS and ES retained significance but the survival advantage of
trial entry for ES became nonsignificant. For both OS and ES diagnosed since 1985, patients whose main treatment centre was a
nonspecialist hospital had a lower survival rate.
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Among persons aged under 40 years, osteosarcoma (OS) and
Ewing’s sarcoma (ES) are the most frequently occurring malignant
bone tumours (Draper, 1985; Hartley et al, 1991). Some cases of
chondrosarcoma also occur, although this is usually a low-grade
tumour often curable by surgery alone.
Survival rates for children aged under 15 years in Great Britain
have improved substantially (Stiller, 1994). For OS, two-year
actuarial survival increased from 45% in 1980–82 to 68% in 1989–
91, while for ES there was an improvement from 55 to 85% over the
same period.
Adults with OS have a worse prognosis than children (Hartley
et al, 1992). In a national study of cancer survival trends in
England and Wales, five-year relative survival rates for adults with
bone cancer diagnosed during 1971–1975, 1976–1980, 1981–1985
and 1986–1990 were 29, 36, 40 and 51%, respectively (Coleman
et al, 1999). These results were for all patients aged 15 years and
over, however, and did not distinguish between histological types.
In England and Wales, age-standardised mortality from all
malignant bone tumours (ICD 170) at age 10–19 years (based on a
uniform population) fell from 8.9 per million in 1981–1984 to 5.7
in 1989–1992, a decrease of 36%, whereas at age 20–44 years it fell
from 2.9 per million in 1981–84 to 2.7 in 1989–92, a decrease of
only 6%. As there is no evidence for any substantial change in
incidence, and allowing for the interval between diagnosis and
death (among children, most deaths from bone cancer occur at 1–
2 years after diagnosis though there is substantial further mortality
for some years after), these results strongly suggest that the
improvements in survival from bone sarcoma in children which
took place during the 1980s extended to patients diagnosed at up
to age 17 or 18 years. For older patients, however, there is little
evidence from mortality data that there has been any improvement
in survival.
There was a substantial improvement in the survival of children
with OS in Britain between the late 1970s and mid 1980s (Stiller
and Bunch, 1990) and this was concentrated among children
treated at paediatric oncology centres, who during 1981–1984 had
a significantly higher survival rate than those treated elsewhere
(Stiller, 1988). For children with ES, there was little change in
national survival rates over the same period (Stiller and Bunch,
1990), but throughout 1977–1984 there was a significantly higher
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(Stiller, 1988).
The only published study of patterns of care and survival from
bone tumours in adults concerned patients with OS from the South
Thames Regions of England registered during 1963–82, almost
entirely before the more recent increase in survival of young
patients associated with more effective chemotherapy (Gill et al,
1988). The effect of entry to trials on survival from bone sarcoma
has not previously been assessed.
The objectives of the present study were to calculate population-
based survival rates for OS and ES among patients aged under 40
years; to determine why the marked decrease in bone cancer
mortality among the population aged under 20 years has not been
seen in the 20–39 year age group; to determine the proportion of
patients treated at specialist centres or entered in clinical trials and
to investigate the effects of these factors on survival.
PATIENTS AND METHODS
Virtually all patients aged under 15 years at diagnosis were already
included in the National Registry of Childhood Tumours (NRCT)
(Stiller et al, 1995). For the age group 15–39 years, the principal
sources were the regional cancer registries in England and the
national cancer registries of Scotland and Wales. Many young
people with bone sarcomas are treated by members of the
UKCCSG and included in the UKCCSG Register; for those aged
15 years and over, the UKCCSG Register was an independent
source of ascertainment; UKCCSG patients below this age were
already in the NRCT. Specialist bone tumour registers in several
regions and the Birmingham Bone Tumour Service supplied lists
of eligible cases. Lists of patients entered in national and
international trials for OS and ES were provided by the Medical
Research Council (MRC) Cancer Trials Office and the UKCCSG,
respectively, and linked with registration records.
Incident cases of bone cancer during the study period were
classified on the basis of the best available information on the
diagnosis for each case.
There were 2843 patients with a malignant bone tumour
diagnosed as a first cancer before age 40 years during 1980–
1994. The 32 patients who had a bone cancer as a second or later
malignancy are not considered here.
Osteosarcoma was the most common subgroup, accounting for
1349 cases (47%). Incidence was highest at age 10–19 years.
Overall, 59% of OSs were diagnosed in males. The proportion of
males was highest at age 15–24 years (64%), while among children
aged under 10 years there was a slight female excess (55%).
Osteosarcoma is predominantly a tumour of the long bones of the
limbs. In this series, 75% of cases with known primary site arose in
the legs and 12% in the arms. Only 11% of primaries were in the
axial skeleton. The proportion of axial primaries was higher at age
25 years and over (28%).
Ewing’s sarcoma, including peripheral primitive neuroecto-
dermal tumour (pPNET) of bone, was the second most common
subgroup, with 849 (30%) cases. In the first 10 years of life it
was the most frequent type of bone cancer. Incidence reached
its peak at age 10–14 years and declined sharply throughout
early adulthood. The overall male excess (58%) was similar to that
for OS, and it was less pronounced (53%) among children
aged under 15 years. The most frequent primary sites for ES were
the leg (35% of tumours of known primary site) and the pelvis
(26%). Pelvic primaries were extremely rare before the age of 5
years but otherwise there was little variation in primary site
with age.
Chondrosarcoma accounted for 307 (11%) cases, other specified
tumours for 245 (8%) and unspecified tumours for 93 (3%).
The present analyses of patterns of care and survival are
restricted to OS and ES.
Main (nonsurgical) treatment centre for clinical trial patients
was defined as the hospital from which the patient was enrolled in
the trial. For nontrial patients, it was defined as the highest level
hospital (in the classification below) at which there was evidence
from any data source that the patient received nonsurgical
treatment within 2 months of diagnosis. Treatment centres were
classified as follows:
BTS: the two supra-regional Bone Tumour Services in London
and Birmingham;
UKCCSG: the 20 paediatric oncology centres affiliated to the
UK Children’s Cancer Study Group (from 1990, some London
BTS patients were registered with the UKCCSG but for all the
analyses presented here they have been counted as BTS);
Other teaching hospitals: the remaining 26 hospitals in
geographical proximity to and attached to medical schools;
Nonteaching hospitals: the remaining 82 hospitals treating
study patients.
Surgical centres were identified from registrations and grouped
as BTS and all other hospitals.
All study patients in the NRCT for whom a death certificate has
not been received are flagged in the National Health Service
Central Registers (NHSCR). Death certificates for persons dying of
neoplasms at age 15–19 years are also available from the NRCT.
Study patients aged 15–39 years at diagnosis were submitted for
flagging at NHSCR. NHSCR provided death certificates for flagged
patients who had died, together with notifications of emigration
resulting in loss to follow-up. All flagged patients not known to
have died or emigrated were assumed to be alive on 31st January
2003. Follow-up information was available for 96% (1297) of
patients with OS and 98% (831) of those with ES.
Survival rates were calculated by the Kaplan–Meier method and
univariate analyses performed using the log-rank test (Peto et al,
1977). Multivariate analyses of survival were carried out using
Cox’s proportional hazards analysis (Cox, 1972). All survival
analyses were carried out using the statistical software package
Stata, Version 7 (StatCorp, College Station, TX, USA).
RESULTS
Referral patterns
Table 1 shows the numbers of patients with OS and Ewing’s
sarcoma classified by main treatment centre. Referral to BTS
increased in successive periods, reaching 38% of patients for
whom this information was known for OS and 30% for ES by
1990–1994. Between 1980–1984 and 1990–1994, the proportions
referred to nonteaching hospitals fell from 24 to 5% for OS and
from 20 to 7% for ES. Referral to hospitals with fewer than two new
study patients per year also fell, with the decrease being more
marked for OS (from 36 to 10%) than for ES (from 31 to 19%). The
proportion of patients at nonteaching centres increased with age
for both diagnostic groups.
Information on surgical centre was available from 1982 onwards.
Overall, 53% (612/1151) of patients with OS were referred to a BTS
for surgery. The proportion so referred increased from 35% in
1982–1984 to 54% in 1985–1989 and 65% in 1990–1994. Referral
rates by age were 55% at 0–9 years, 65% at 10–14, 52% at 15–19
and 45% at 20–39 years. For ES, local therapy has often been by
radiotherapy alone for axial primaries (Craft et al, 1998) and also
for many limb primaries until the mid 1980s (Craft et al, 1997).
Surgical centre was therefore only analysed for patients with limb
primaries diagnosed during 1985–1994. Among this group, 51%
(139 out of 274) were referred to a BTS for surgery. The referral
rate varied little with age (results not shown).
Population survival from bone sarcoma
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During 1983–1986, there was one OS trial for which patients aged
under 40 years with operable tumours were eligible (Bramwell
et al, 1992), including those with metastases at diagnosis
(Bramwell et al, 1997). While intended for patients with limb
primaries, this trial also included a few with axial tumours. During
1987–1992, two trials were open simultaneously. The first was
for patients with localised limb primaries (Souhami et al, 1997)
and the second was for patients with metastatic disease or axial
tumours (Vou ˆte et al, 1999). Entry rates overall were similar in
1983–1986 (47%) and 1987–1992 (50%). They were higher for
children and adolescents aged under 20 years (55%) than for
patients aged 20–39 years (36%). Entry rates were higher among
BTS patients (68%) than those treated elsewhere (43%).
Three successive trials for ES were open during the study period.
The first of these was the UKCCSG study ET-1, which actually
began in 1978 (Craft et al, 1997). The entry rate during 1980–1986
was 27% overall, 43% for children aged under 15 years and 19% for
adolescents aged 15–19 years. The upper age limit for the study
was 40 years, but only 4% of patients aged 20–29 years and none
aged 30–39 were entered. Among children and adolescents, entry
rates were much higher at (non-BTS) UKCCSG centres (59%) than
elsewhere (14%).
Table 1 Main treatment centre for patients with osteosarcoma and Ewing’s sarcoma
BTS UKCCSG Other teaching Nonteaching Unknown Total
(i) Treatment centre classified by type (see text)
Osteosarcoma
Age (years)
0–9 14 76 9 10 1 110
10–14 110 162 37 27 4 340
15–19 127 52 184 61 42 466
20–39 119 0 205 64 45 433
1980–1984 70 88 173 105 45 481
1985–1989 151 89 150 38 26 454
1990–1994 149 113 112 19 21 414
Total 370 290 435 162 92 1349
Ewing’s sarcoma
Age (years)
0–9 12 112 8 4 0 136
10–14 36 164 25 19 0 244
15–19 50 39 89 28 18 224
20–39 46 0 137 40 22 245
1980–1984 12 100 105 54 12 283
1985–1989 50 110 88 18 18 284
1990–1994 82 105 66 19 10 282
Total 144 315 259 91 40 849
(ii) Treatment centre classified by annual number of study patients (osteosarcoma and Ewing’s sarcoma combined) referred per year
X10 (BTS) 5–9 2–4 0–1 Unknown Total
Osteosarcoma
Age (years)
0–9 14 19 46 30 1 110
10–14 110 65 97 64 4 340
15–19 127 85 128 84 42 466
20–39 119 60 115 94 45 433
1980–1984 70 83 128 155 45 481
1985–1989 151 73 126 78 26 454
1990–1994 149 73 132 39 21 414
Total 370 229 386 272 92 1349
Ewing’s sarcoma
Age (years)
0–9 12 21 76 27 0 136
10–14 36 49 97 62 0 244
15–19 50 62 56 38 18 224
20–39 46 56 58 63 22 245
1980–1984 12 62 114 83 12 283
1985–1989 50 74 86 56 18 284
1990–1994 82 52 87 51 10 282
Total 144 188 287 190 40 849
Population survival from bone sarcoma
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et al, 1998). The entry rate overall for 1987–1992 almost doubled
to 52%. Entry increased in all age groups below 30 years, reaching
72% for children under 15, 56% for adolescents aged 15–19 years
and 33% for young adults aged 20–29 years. The upper age limit
was 30 years and there were no entries above that age. Entry rates
from UKCCSG and BTS centres (73%) were higher than elsewhere
(19%).
The third trial, EICESS-92, was an international collaboration
between UKCCSG, MRC and the German Co-operative Ewing’s
Sarcoma Study Group (Schuck et al, 2003). The upper age limit
was 40 years. During 1993–1994, the first 2 years that this trial was
open, the overall entry rate rose to 62%. This was largely due to an
increase in the entry rate for children to 83%. Entry rates were 84%
at UKCCSG and BTS centres and 15% elsewhere.
Survival
Table 2 shows the results of univariate analysis of survival by age,
sex, primary site and year of diagnosis. Table 3 shows 5 year
survival by period of diagnosis and age group. For OS diagnosed
during 1990–1994, children aged under 10 years had a somewhat
higher survival rate than older patients. Female subjects had a
higher survival rate than males (Table 2). There was no evidence of
a difference in survival between the sexes among children aged 0–
14 years but female subjects had markedly higher survival in the
older age groups. The variation in survival with age was present for
both sexes, although less marked for female subjects (results not
shown). Patients with skull tumours had an exceptionally high
survival rate. Those with primaries in other axial sites (spine, ribs
and sternum, pelvis) or in the arm had lower than average survival.
Five-year survival rates during 1980–1984, 1985–1989 and 1990–
1994 were 42% (95% CI: 37, 46), 54% (95% CI: 50, 59) and 53%
(95% CI: 48, 57), respectively (Figure 1). The pattern of substantial
increase in survival between 1980–1984 and 1985–1989 but no
further improvement in 1990–1994 was similar for all age groups
above age 10 years.
For ES, children aged under 15 years had higher survival than
other patients. There was no difference in survival between male
and female subjects. Pelvic primary site was associated with poor
survival. The small number of patients with skull or hand
primaries had a good prognosis. Survival for other axial sites
was similar to that for limb primaries. Five-year survival rates
during 1980–1984, 1985–1989 and 1990–1994 were 31% (95% CI:
26, 37), 46% (95% CI: 40, 51) and 51% (95% CI: 45, 57),
respectively (Figure 2). This pattern of steadily increasing survival
throughout the study period was present in each age group below
20 years, but above that age there was rather little change with
calendar period.
Table 4 shows 5-year survival for patients at different categories
of main treatment centre by period of diagnosis. For OS, survival
Table 2 Univariate analysis of survival by age, sex, primary site and year of diagnosis
Osteosarcoma Ewing’s sarcoma
N 1 year 5 years 10 years PN 1 year 5 years 10 years P
Age (years)
0–4 9 67 67 56 0.39 27 85 52 48 o0.0001
5–9 99 91 58 55 109 89 59 56
10–14 340 86 45 43 242 91 48 42
15–19 446 85 47 41 216 81 30 26
20–24 206 84 52 45 123 77 38 32
2 5 – 2 9 8 2 7 9 4 84 5 6 2 8 2 4 03 2
30–39 115 90 56 49 52 75 48 34
Sex
Male 759 85 47 41 0.031 485 83 43 37 0.61
Female 538 86 53 49 346 87 42 38
Primary site
Skull 52 94 67 67 o0.0001 25 92 56 56 o0.0001
Spine 21 76 43 29 58 79 43 36
Ribs, sternum 21 67 38 33 88 86 45 38
Pelvis 55 64 24 21 206 77 24 21
Arm 157 86 44 35 102 88 53 47
Hand 11 100 73 64
Leg 964 87 51 47 284 90 49 42
Foot 11 73 64 55 24 88 46 42
Unspecified 16 69 50 44 33 64 39 36
Year of diagnosis
1980–1984 469 79 42 36 o0.0001 279 84 31 26 o0.0001
1985–1989 428 89 54 50 274 84 46 40
1990–1994 400 89 53 48 278 86 51 45
Percentage survival rates at 1, 5 and 10 years after diagnosis and P-value from log rank test for heterogeneity.
Table 3 Five-year survival (%) by calendar period and age at diagnosis
Osteosarcoma Ewing’s sarcoma
Age at diagnosis (years)
0–9 10–14 15–19 20–39 0–9 10–14 15–19 20–39
Year of diagnosis
1980–1984 45 39 41 45 40 37 15 35
1985–1989 54 51 54 57 67 49 26 47
1990–1994 71 48 48 55 72 59 47 39
Population survival from bone sarcoma
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elsewhere. In 1985–1989, only the nonteaching hospitals had lower
survival and in 1990–1994 there was relatively little variation.
For ES in all three calendar periods, survival was lower among
patients treated at nonteaching hospitals. During 1985–1994, BTS
and UKCCSG centres had higher survival rates than other teaching
hospitals. Apart from the very few children aged under 10 years,
patients of all ages at nonteaching hospitals had a lower survival
rate. The higher survival at BTS centres was most marked for the
age group 10–14 years.
Five-year survival of patients with OS who had surgery at a BTS
centre in 1982–1984 was 59%, significantly higher than for those
having surgery elsewhere (39%, log rank P¼0.001). More recently,
there was no significant difference in survival between BTS and
other surgical centres (1985–1989, 58 vs 51%, P¼0.26; 1990–1994,
51 vs 55%, P¼0.85).
For OS, there was no significant difference in survival between
trial and nontrial patients diagnosed during 1983–1986 (5-year
survival 52 and 50%, respectively, log rank P¼0.21) or 1987–1992
(5-year survival 50 and 55%, P¼0.45).
Table 5 shows 5-year survival of trial and nontrial patients with
ES. Year of diagnosis was regrouped as 1980–1986, 1987–1992,
1993–1994, to correspond with the periods when successive trials
were open. Survival was higher for trial than for nontrial patients
during the eras of the three successive trials (Figure 3). For
patients aged under 20 years, survival was higher among those in
the trials, but above that age there was no difference in survival
between trial and nontrial patients.
In the univariate analysis of OS, the effects of main treatment
centre and surgical centre differed for patients diagnosed before
and after the end of 1984. Multivariate analysis was therefore
performed for patients diagnosed during 1985–1994. The variables
in the model were sex, age, primary site, main treatment centre and
surgical centre. Results are shown in Table 6. Male sex and primary
site in the spine, ribs and sternum or in the pelvis were confirmed
as adverse prognostic factors. Compared with nonteaching
hospitals as reference category of main treatment centre, survival
of patients at UKCCSG and other non-BTS teaching hospitals was
significantly higher.
For ES also, the effect of main treatment centre differed between
1980–1984 and 1985–1994, and multivariate analysis was there-
fore restricted to the latter period. Trial status was included in the
model as it was significant in univariate analysis. Table 7 shows the
results of two analyses, the first for all patients and the second only
for those with a limb primary; surgical centre was included in the
second analysis. Age 10–24 years and pelvic primary site were
confirmed as adverse prognostic factors. Survival was significantly
higher at BTS, UKCCSG and teaching hospital main treatment
centres than at nonteaching hospitals. In a similar model in which
treatment centre caseload was substituted for type of main
treatment centre, those with fewer than two study patients per
year had a significantly lower survival rate. In the analysis of
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Figure 1 Survival of patients with OS diagnosed at age under 40 years
during 1980–1994, by calendar period of diagnosis.
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Figure 2 Survival of patients with ES diagnosed at age under 40 years
during 1980–1994, by calendar period of diagnosis.
Table 4 Five-year survival (%) for patients at different categories of main treatment centre by calendar period, 1980–1994
Year of diagnosis N BTS UKCCSG Other teaching Nonteaching Unknown P
Osteosarcoma
1980–1984 469 50 51 38 37 34 0.0092
1985–1989 428 54 58 54 37 76 0.077
1990–1994 400 49 55 55 44 56 0.49
Ewing’s sarcoma
1980–1984 279 33 40 31 21 8 0.0003
1985–1989 274 57 52 36 22 47 0.0001
1990–1994 278 57 59 42 11 56 o0.0001
Table 5 Five-year survival (%) for Ewing’s sarcoma trial and nontrial
patients by calendar period and age at diagnosis, 1980–1994
N Trial Non-trial P
Year of diagnosis
1980–1986 386 42 30 0.0047
1987–1992 355 59 42 0.0001
1993–1994 90 54 43 0.093
Age (years)
0–9 136 68 44 0.0005
10–14 242 52 40 0.024
15–19 216 48 19 o0.0001
20–24 123 38 38 0.83
25–39 114 43 44 0.72
Population survival from bone sarcoma
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spatients with limb primaries, the adverse effect of age 10–24 years
remained. Main treatment centre, surgical centre and trial status
were all nonsignificant.
DISCUSSION
Survival from both OS and ES increased markedly between 1980–
1984 and 1985–1989. In the next 5 years, survival increased further
for patients diagnosed with ES before the age of 20 years, although
survival of those diagnosed at age 20–39 years fell back to near the
level for 1980–1984. Among patients with OS diagnosed during
1990–1994, by contrast, only those aged under 10 years
experienced any additional increase in survival compared with
1980–1989. Overall, these results are consistent with the con-
temporaneous decrease in population mortality from bone cancer,
which was more marked at younger ages.
The favourable prognosis for craniofacial OS is in agreement
with clinical reports (Gadwal et al, 2001; Smith et al, 2003). Data
from the SEER Program cancer registries in the US showed no
major difference compared with long bone primaries in an analysis
including patients of all ages, although this did not allow for age,
but the poor prognosis for pelvic OS was confirmed (Dorfman and
Czerniak, 1995). In a more recent study of patients aged under 20
years, survival did not differ substantially by site, but no details
were given (Gurney et al, 1999). In a recent clinical series, 40% of
patients aged under 40 years with a pelvic OS had an inoperable
primary or distant metastases (Grimer et al, 1999).
Among patients aged under 20 years with OS, we found that
survival of those aged 10–14 years was lower than for younger
children but there was no further deterioration of prognosis in the
15–19 year age group. In the USA, by contrast, survival was worse
at age 15–19 than at age 10–14 years and children aged under
10 years at diagnosis also had a somewhat lower survival rate,
particularly before 1985 (Gurney et al, 1999). The effects of age on
survival in clinical series have been similarly inconsistent
(Nagarajan et al, 2003).
Survival from OS was significantly higher for female than for
male subjects. This is consistent with the higher metastasis-free
survival for female subjects in the Scandinavian Sarcoma Group
 1980–1986 Nontrial  N=282
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 1993–1994 Nontrial  N=35
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Figure 3 Survival of patients with ES diagnosed at age under 40 years
during 1980–1994, by calendar period of diagnosis and trial status. The
periods 1980–1986, 1987–1992 and 1993–1994 correspond, respec-
tively, to periods of entry to the first UKCCSG study, the second UKCCSG-
MRC study and the international trial EICESS-92.
Table 6 Results of Cox proportional hazards analysis for osteosarcoma
diagnosed during 1985–1994
HR (95% CI)
Sex
Male 1 (reference)
Female 0.72 (0.59, 0.88)
Age (years)
0–9 1 (reference)
10–14 1.30 (0.87, 1.94)
15–19 1.13 (0.74, 1.72)
20–39 1.06 (0.68, 1.63)
Primary site
Skull 0.76 (0.43, 1.37)
Spine, ribs, sternum 1.84 (1.10, 3.10)
Pelvis 3.04 (2.07, 4.46)
Upper limb 1.10 (0.82, 1.47)
Lower limb 1 (reference)
Unspecified 2.34 (1.13, 4.84)
Main treatment centre
BTS 0.86 (0.56, 1.32)
UKCCSG 0.60 (0.39, 0.93)
Teaching 0.69 (0.47, 1.00)
Nonteaching 1 (reference)
Unknown 0.42 (0.23, 0.75)
Surgical centre
BTS 1 (reference)
Other 1.15 (0.88, 1.52)
HR¼Hazard ratio.
Table 7 Results of Cox proportional hazards analysis for Ewing’s
sarcoma diagnosed during 1985–1994
HR (95%CI)
(i) All primary sites (ii) Limb primaries only
Sex
Male 1 (reference) 1 (reference)
Female 0.94 (0.75, 1.18) 0.89 (0.63, 1.27)
Age (years)
0–9 1 (reference) 1 (reference)
10–14 1.61 (1.04, 2.50) 2.05 (1.06, 3.97)
15–19 2.04 (1.27, 3.28) 3.08 (1.50, 6.31)
20–24 2.09 (1.21, 3.61) 3.18 (1.42, 7.10)
25–39 1.63 (0.94, 2.82) 1.95 (0.82, 4.61)
Primary site
Skull 0.46 (0.19, 1.13) —
Spine, ribs, sternum 1.20 (0.87, 1.66) —
Pelvis 1.64 (1.24, 2.18) —
Upper limb 0.87 (0.59, 1.28) 0.89 (0.61, 1.31)
Lower limb 1 (reference) 1 (reference)
Unspecified 1.18 (0.69, 2.00) —
Main treatment centre
BTS 0.44 (0.27, 0.71) 0.54 (0.24, 1.20)
UKCCSG 0.50 (0.30, 0.84) 0.57 (0.24, 1.32)
Teaching 0.64 (0.43, 0.97) 0.58 (0.29, 1.15)
Non-teaching 1 (reference) 1 (reference)
Unknown 0.42 (0.22, 0.80) 0.84 (0.29, 2.48)
Surgical centre
BTS — 1 (reference)
Other — 1.32 (0.82, 2.12)
Trial status
Trial 1 (reference) 1 (reference)
Nontrial 1.28 (0.97, 1.68) 1.31 (0.87, 1.97)
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unknown gender-dependent genetic factor (Smeland et al, 2003).
We found no difference in survival from ES between male and
female subjects, whereas in the SEER data 5-year relative survival
rates were 35% for males and 52% for female subjects (all ages,
1973–1987) and 50% for males, 68% for female subjects (age 0–19
years, 1975–1994). Survival rates from ES in the US have not been
published for all ages, but among patients aged under 20 years
pelvic primary site was associated with a low 5-year survival of
under 35% (Gurney et al, 1999). The poor prognosis for pelvic
tumours was also found in a large, combined clinical trial series
from the UK and Germany and may be attributable to the larger
tumour volume typical of that site (Cotterill et al, 2000).
A striking feature of the present study was the relation of
survival to age for ES. The prognosis at age 15 years and over was
much worse than for children below that age. In the UK – Germany
clinical trial series, the age-related difference in survival was most
marked with a cutoff point of 15 years (Cotterill et al, 2000). In the
US, survival at age 10–14 years was lower than that for younger
children, but adolescents aged 15–19 years had very similar
survival to the 10–14 years age group (Gurney et al, 1999). In a
study of patients with ES or pPNET treated on the adult sarcoma
unit of the Royal Marsden Hospital, survival was higher for
patients aged 20 years and over than for those aged 15–19 years
(Verrill et al, 1997). That study only included 59 patients overall,
and 51 aged 15–39 years. Moreover, patients with extra-osseous
primaries were also included, although tissue of origin was not
found to be of prognostic importance. In the present much larger
study, there was a suggestion of increasing survival above age 20
years but this fell far short of statistical significance.
Survival of children aged under 15 years with OS during 1977–
1980 did not vary between paediatric oncology centres and other
hospitals, whereas in 1981–1984 there was a substantial increase in
survival at paediatric oncology centres which did not take place
elsewhere (Stiller, 1988). In the present study, covering 1980–1994,
there was some indication that survival was higher at specialist
centres than at other hospitals, but the differences were not always
statistically significant. This is similar to the finding of non-
significantly higher survival at major centres by Gill et al (1988),
although their study largely related to an earlier period when
modern combination chemotherapy for OS was not widely used
and survival was much lower. During the 10 years for which data
were available from national trials, slightly under half of the
patients with OS in this study were entered in a trial. Survival was
very similar for trial and nontrial patients. To be eligible for
inclusion in the trials, patients had to have operable, high-grade
OS and not to have other medical conditions which might preclude
them from receiving treatment according to the protocol, and the
maximum interval from biopsy to randomisation was 35 days
(Bramwell et al, 1992; Souhami et al, 1997; Vou ˆte et al, 1999). Most
of these criteria would tend to exclude patients with a worse
prognosis, although the histological criterion would exclude lower
grade tumours with a better prognosis. There has been little
progress in treatment and survival for OS since the early 1980s. It
seems likely that trial and nontrial patients would have been
similarly treated in the same hospitals and it is therefore not
surprising that they should have similar survival rates. In the US
Multi-Institutional Osteosarcoma Study, survival was similar for
randomised patients and those who declined randomisation but
were treated according to protocol (Link et al, 1991). The higher
survival rate for patients who had surgery at a supraregional bone
tumour centre was confined to the early years of the study, with
little sign of any variation more recently. Within the European
Intergroup trials during 1983–1993, survival rates were identical
for patients treated at each of the three largest surgical centres
despite different treatment policies (Grimer et al, 2002).
Children aged under 15 years with ES had a higher survival rate
at paediatric oncology centres compared with other hospitals
throughout the period 1977–1984 (Stiller, 1988). In the present
study, survival was higher at specialist bone tumour treatment
centres and paediatric oncology centres than at other hospitals,
including other teaching hospitals. Survival of children and
adolescents from ES was consistently higher throughout the
study period for patients entered in national trials than for those
who were not entered. Tumour stage was not available for this
study and it is theoretically possible that any apparent effects
of treatment centre and trial status on survival were due to
confounding of these variables with stage. However, as primary
site was an important prognostic factor associated with tumour
burden, and trials were open for patients with both localised and
metastatic disease, this seems unlikely. There was a maximum
interval of 3 weeks between diagnosis and starting treatment for
patients to be eligible for EICESS-92 (Paulussen et al, 2001), but no
maximum period between diagnosis and starting treatment was
specified for the two earlier trials (Craft et al, 1997; Craft et al,
1998). Patients with any primary site and those with metastatic
disease at diagnosis were eligible for all three trials.
Our study has several strengths. We analysed a large series of
patients from population-based cancer registries that would not
be subject to the selection bias that can affect studies based on
hospital data. This was a national study with the ability to describe
and analyse patterns of care and survival for the whole country.
While it might be possible to obtain more detailed data in a study
of a smaller geographical area, such an area might have atypical
patterns of care. Follow-up through national record systems was
virtually complete. Information on place of treatment was available
for the great majority of patients and trial status was determined
by direct linkage with clinical trial databases.
The study also has a number of limitations. Information on
stage of disease was not available and therefore we could not
identify patients with an obviously poor outlook at diagnosis who
may not have been referred to a tertiary centre or entered in a trial
for that reason. If stage had been available, this information would
not itself have been completely reliable as it need not have been
based on identical investigations in every case. We were able,
however, to make some allowance for extent of disease by using
information on primary site, which is associated with tumour
burden in both OS and ES. The effects of trial status and treatment
centre in multivariate survival analyses which also included
primary site were broadly similar to those in the univariate
analyses. The most recent patients in the study were diagnosed just
over 10 years ago. Meanwhile, entry rates to clinical trials could
have increased, referral patterns could have changed and standards
of treatment could have improved, especially in nonteaching
hospitals. Survival studies are necessarily historical, however, and
the results of clinical trials that were open at the end of our study
period are yet to be published. Only a further study could
determine whether patterns of care have changed more recently
and, if so, how they have influenced survival.
In conclusion, within the limitations of an analysis of historic
data with incomplete allowance for confounding factors, this study
provides evidence of higher survival rates at tertiary centres for
patients with both of the main types of bone sarcoma diagnosed at
ages up to 40 years.
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